Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Pract
2026-05-05
The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) prevents unwanted protein degradation during extraction and sample preparation, making it suitable for workflows where divalent cation preservation is critical. It is not intended for use in protocols that require metalloprotease inhibition via chelators like EDTA.
Neticonazole Hydrochloride: Imidazole Antifungal with Oncolo
2026-05-05
Neticonazole Hydrochloride is a clinically validated imidazole antifungal with additional antitumor properties. It inhibits fungal cell membrane synthesis and exosome-mediated cancer progression, demonstrating efficacy in both superficial mycoses and colorectal cancer models. Its dual action streamlines translational workflows for mycosis and oncology research.
Trelagliptin Succinate: Bridging Diabetes and Bone Health
2026-05-04
This thought-leadership article explores Trelagliptin succinate’s unique role as a long-acting, selective DPP-4 inhibitor in advancing both type 2 diabetes and bone health research. Integrating mechanistic insights—especially RUNX2-mediated osteoblastic differentiation—alongside translational strategies, it draws on recent evidence to guide researchers toward high-impact, reproducible workflows. The discussion elevates beyond standard product descriptions, positioning APExBIO’s Trelagliptin succinate as a tool for pioneering dual-domain discovery.
BMX-IN-1: A Highly Selective BMX Kinase Inhibitor for Resear
2026-05-04
BMX-IN-1 is a potent, irreversible BMX kinase inhibitor enabling precise modulation of Tec family signaling for cancer and infectious disease research. Its nanomolar potency and selectivity make it ideal for dissecting apoptosis induction and cell cycle arrest at the G0/G1 phase in cell-based assays.
GW4064: Non-Steroidal FXR Agonist Empowering Metabolic Resea
2026-05-03
GW4064 stands out as a benchmark non-steroidal FXR agonist for dissecting bile acid, cholesterol, and triglyceride regulation in metabolic and fibrotic disease models. Recent breakthroughs, including its application in nanoparticle-induced liver fibrosis, spotlight GW4064’s unique ability to illuminate the FXR/TLR4/ferroptosis axis. This guide delivers actionable protocols, troubleshooting strategies, and expert insights for maximizing the compound’s research potential.
BV6 and the Next Chapter of Regulated Cell Death in Cancer
2026-05-02
This thought-leadership article examines BV6 as a selective IAP antagonist and Smac mimetic, integrating the latest mechanistic insights from lysoptosis research to guide translational scientists. It contextualizes BV6’s mechanistic impact within the broader landscape of regulated cell death, contrasts its utility against emerging cell death modalities, and provides actionable experimental parameters for maximizing its translational relevance in oncology and endometriosis models.
Neuroligin 1 Loss Drives Repetitive Behaviors via Striatal P
2026-05-02
This study uncovers how Neuroligin 1 deletion in D2-expressing striatal neurons leads to excessive repetitive behaviors through hyperactivation of the PKC signaling pathway. The findings provide mechanistic insight into the cellular basis of autism spectrum disorder (ASD)-like behaviors and suggest new avenues for targeted intervention.
M344: Histone Deacetylase Inhibitor for Cancer Research Work
2026-05-01
M344 stands out among histone deacetylase inhibitors due to its submicromolar potency and proven efficacy in breast cancer, neuroblastoma, and medulloblastoma models. This article details experimental workflows, troubleshooting, and key protocol parameters that unlock the full potential of M344 in advanced cancer and HIV-1 latency research.
DMXAA (Vadimezan): Advanced Insights into Endothelial Apopto
2026-04-30
Explore how DMXAA (Vadimezan) redefines cancer biology research as an apoptosis inducer and vascular disrupting agent. This article provides a deep-dive into endothelial-specific mechanisms, unique protocol optimizations, and latest findings on STING-JAK1 signaling—offering actionable guidance and advanced analysis beyond existing literature.
Topotecan as a Topoisomerase I Inhibitor: Advances and Impli
2026-04-30
This review evaluates topotecan, a semisynthetic topoisomerase I inhibitor, highlighting its unique mechanism of inducing DNA damage and apoptosis in cancer cells. The pharmacokinetic properties, clinical efficacy, and application in combination chemotherapy are discussed, with implications for translational cancer research.
Haloprogin: Mechanistic Insights & Translational Value in An
2026-04-29
Explore the unique mechanistic profile of Haloprogin, a broad-spectrum topical antimicrobial, and discover how its nuanced activity against dermatophytes and Gram-positive bacteria informs advanced research applications. This article delivers a deeper analysis—distinct from protocol guides—by decoding Haloprogin’s translational impact and assay design considerations.
PA-824: Bicyclic Nitroimidazole Derivative Advances TB Resea
2026-04-29
PA-824 empowers tuberculosis researchers with potent dual-action inhibition, reproducible assay performance, and robust activity against both drug-sensitive and drug-resistant Mycobacterium tuberculosis. This guide translates cutting-edge reference findings into actionable workflows and troubleshooting strategies for maximizing the value of this high-purity APExBIO research compound.
Distinct Cell Death Pathways in ALL: Microtubule Depolymeriz
2026-04-28
This study demonstrates that primary acute lymphoblastic leukemia (ALL) cells respond to microtubule depolymerization with phase-specific cell death mechanisms: apoptosis in M phase and a distinct, caspase-independent pathway in G1. These findings refine our understanding of microtubule targeting agents' clinical actions and reveal new avenues for targeting ALL.
Dlin-MC3-DMA: Ionizable Cationic Liposome for Potent RNA Del
2026-04-28
Dlin-MC3-DMA stands out as an ionizable cationic liposome lipid, delivering unmatched potency and safety for mRNA and siRNA therapeutics. Its pivotal role in lipid nanoparticle platforms accelerates gene silencing, vaccine formulation, and cancer immunochemotherapy with precision and reproducibility.
AptaBLE: Deep Learning Enhances Aptamer-Protein Binding Pred
2026-04-27
AptaBLE introduces a deep learning framework that accurately predicts aptamer-protein interactions and enables de novo aptamer generation, outperforming prior computational methods. This advancement streamlines therapeutic and diagnostic aptamer discovery, reducing reliance on labor-intensive SELEX protocols.
463 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page